Navigation Links
Amarin Secures Global Intellectual Property Rights for Lipid Programs
Date:3/3/2008

LONDON, March 3 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it has signed an exclusive license with Scarista Limited ("Scarista") for the development and commercialization rights to a broad intellectual property portfolio in the field of lipid science. This intellectual property portfolio is complementary to Amarin's existing lipid-based development programs including AMR101 and its targeted lipid transport technology. The transaction consideration comprises an upfront fee to Scarista of $0.5 million and royalties upon commercialization.

In 2004, Amarin licensed rights to this portfolio, covering applications in diseases of the central nervous system for North America, the EU and Japan. This new license provides Amarin with rights to all remaining therapeutic areas and all territories worldwide.

Thomas Lynch, Amarin's Chairman and Chief Executive Officer, commented "This is an important strategic step for Amarin that strengthens our position to establish global partnerships with our lipid programs. In addition, access to broader potential applications will allow us to take advantage of new opportunities outside the CNS field, such as cardiovascular disease."

Declan Doogan M.D., Amarin's Head of Research and Development, added "The field of lipid science has matured significantly in the past two decades, and now contributes a range of important prescription drug treatments for various medical conditions associated with the vascular system, including cardiovascular disease. In addition, real medical benefits have been identified with new development stage candidates based on lipid science, achieving recognition in prestigious scientific publications. Amarin enjoys a prominent pla
'/>"/>

SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Amarin Appoints Dr. William Mason as Lead Independent Director
2. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
3. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
4. Amarin Signs Agreement to Acquire Ester Neurosciences
5. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
6. Amarin Announces Initiation of Cardiovascular Development Strategy
7. Amarin to Present at 4th Annual Bio Investor Forum
8. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
9. Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs
10. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
11. Taligen Therapeutics Secures Series B Financing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...ATO, Calif., Nov. 30 Bio...ed today that the Food and Drug Administration (FD...minopyridine (3,4-DAP), amifampridine phosphate, f...henic Syndrome (LEMS). 3,4-DAP has previously rec...n October 2009, the Committee for Medicinal Produc...
(Date:11/30/2009)... , LONDON, November 30 Apa...was named Europe,s fastest growing,Biotech/Pharmac...e Deloitte,2009 Technology Fast 500 for EMEA (Euro...l ranking is based on a companies, five-year reven...f 8,318% over this period. This,achievement places...
(Date:11/27/2009)... PARIS, November 27 Sta...rket Oralair(R) in both adults and children,throug...st country where,Oralair(R) has been marketed, was... is now registered in Austria, Belgium, Bulgaria, ...ny, Greece, Hungary, Ireland, Italy,Latvia, Lithu...
(Date:11/25/2009)... Ambassador to Speak at Economic Club o...a (Vocus) November 25, 2009 -- Ambassador to Speak...Appia, French Ambassador for International Investm...Agency ,To view a biography of David Appia go to ...ppia is available to meet with press to discuss re...
Breaking Biology Technology:FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4ApaTech is Europe's Fastest Growing Lifescience Company 2ApaTech is Europe's Fastest Growing Lifescience Company 3ApaTech is Europe's Fastest Growing Lifescience Company 4STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3French Ambassador for International Investment to Visit Toronto December 11 2
... Increasing Case Volumes Drive 78 Percent Revenue ...o the Prior Year Period , , ALISO VIEJO, Calif., ...emier anatomic pathology and molecular testing ser...the pharmaceutical industry, today reported prelim... year ended December 31, 2008. Financial results ...
...arch 11 XTL Biopharmaceuticals Ltd. (Nasdaq: XT...nary General Meetings ("EGMs") were postponed for ...ation due to the absence of a quorum. The postpone... Kiryat Weizmann Science Park, Rehovot, Israel 761... 18, 2009. , , Any proxy votes received at any ti...
...H, Switzerland, March 11 Simbionix,the world,s le... VirtaMed, a,Swiss medical engineering company, an...mbionix will exclusively distribute, market, and p...ed virtual reality hysteroscopy simulator. , S...ors for minimal,invasive surgery. "This new agreem...
Other Biology Technology:Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008 2Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008 3Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008 4Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008 5Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008 6Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008 7Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008 8Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008 9Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008 10Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008 11Simbionix Increases Product Offerings for OB/GYN Physicians 2
(Date:11/30/2009)...ntific organisation is needed to monitor the commi...t Copenhagen to cut their deforestation rates, acc... Existing government agencies and research groups ...atellite images of the Earth,s surface collected e... paper published by Dr Alan Grainger in the Proce...
(Date:11/30/2009)... Clemson University researchers Ron Falta and Larr...Protection Agency grant to study the safe storage ... deep below the earth,s surface. , With carbon d...d to be the leading cause of global warming, geolo...g alternatives for reducing emissions using curren...
(Date:11/30/2009)...ase is available in German . , The DFG has ... Research Centres as of 1 January 2010. This decis...ttee in Bonn. The new centres will initially be fu...n addition, 20 percent overhead funding for indire...he centres, research topics range from modern pros...
Breaking Biology News(10 mins):World forest observatory needed to monitor vital role of forests in climate deal 2DFG approves funding for 17 new collaborative research centers 2DFG approves funding for 17 new collaborative research centers 3DFG approves funding for 17 new collaborative research centers 4DFG approves funding for 17 new collaborative research centers 5DFG approves funding for 17 new collaborative research centers 6DFG approves funding for 17 new collaborative research centers 7DFG approves funding for 17 new collaborative research centers 8DFG approves funding for 17 new collaborative research centers 9nContact Announces Initiation of Clinical Trials for the Treatment of Atrial Fibrillation in Open Chest Procedures 6278 1nContact Announces Initiation of Clinical Trials for the Treatment of Atrial Fibrillation in Open Chest Procedures 6278 2Par Pharmaceutical Receives Final Approval to Market Generic Ultram 28R 29 ER 6276 1Par Pharmaceutical Receives Final Approval to Market Generic Ultram 28R 29 ER 6276 2Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 1Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 2Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 3Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 4Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 5Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 6Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 7Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 8Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 9Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 10
...overed a new technique for turning embryonic stem ...what could prove a significant breakthrough in the... University of Manchester team, working with colle... genetically manipulate the stem cells so that the...iption factor. , Stem cells have the ability to b...
...f Pittsburgh of UPMC a national leader in the use...or children in heart failure is part of a collabo...on grant from the National Institutes of Health (N...cifically for small children. , VADs are mechanic...e heart and offer lifesaving support, most often a...
...end bird feeders in their backyards each year, oft... survey of research on the topic finds that feedin...birds. , Published as a Frontiers in Ecology an...ology.org ), the meta-analysis led by Gillian Robb...rhop (University of Exeter, UK) reviewed results f...
Other Biology News:Stem cell breakthrough offers diabetes hope 2Children's Hospital leads projects to develop nation's first heart assist devices for young children 2Children's Hospital leads projects to develop nation's first heart assist devices for young children 3Food for thought 2
Rabbit Anti-MD-2 (IN) Polyclonal Antibody, Unconjugated from AnaSpec
Anti-MPM-2, phospho-Ser / Thr-Pro (Mitotic protein monoclonal #2) Antibody, Agarose Conjugated from Upstate
Goat Anti-Human Bcl-2, phospho (Thr74) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Mouse Anti-Calcium Channel alpha 2 delta-2 Monoclonal Antibody, Unconjugated, Clone 42 from BD Biosciences Pharmingen
Biology Products: